ImmunoCellular Therapeutics Ltd.
IMUC.WS
IMUC.WS was delisted on the 16th of October, 2018.
4 hedge funds and large institutions have $511K invested in ImmunoCellular Therapeutics Ltd. in 2017 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, reducing their positions, and closing their positions.
6% more capital invested
Capital invested by funds: $480K → $511K (+$31K)
0% more funds holding
Funds holding: 4 → 4 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$18.5K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$52 |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AFM
1
Anson Funds Management
Dallas,
Texas
| $373K | – | – | – |
|
|
SM
2
Sabby Management
Miami Beach,
Florida
| $113K | +$18.5K | +35,296 | +9% |
|
3
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $25K | – | – | – |
|
|
4
UBS Group
Zurich,
Switzerland
| – | +$52 | +100 | +8% |
|
IMUC.WS Hedge Fund Activity: Q1 2017 in Review
4 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in ImmunoCellular Therapeutics Ltd. (IMUC.WS) for Q1 2017, worth a combined $511K — up 6.5% from $480K a quarter earlier.
Fund positioning in IMUC.WS was balanced in Q1 2017: 0 funds opened new positions, 0 closed out, 2 added to existing stakes and 0 trimmed.
The largest buyer was Sabby Management, adding an estimated $18.5K.
- 4 institutional investors held ImmunoCellular Therapeutics Ltd. (IMUC.WS) as of Q1 2017, unchanged from Q4 2016.
- Funds reported $511K of ImmunoCellular Therapeutics Ltd. stock for Q1 2017, up 6.5% quarter-over-quarter.
- 0 funds opened new ImmunoCellular Therapeutics Ltd. positions in Q1 2017 and 0 closed out.
- The largest ImmunoCellular Therapeutics Ltd. buyer in Q1 2017 was Sabby Management, an estimated $18.5K added.
Based on aggregated 13F filings for Q1 2017.